AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02456389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-based, escalating levels of care
Description: Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
Study NCT02456480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001
Description: topical gel
Study NCT02456480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical gel
Study NCT00204243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: surgically implanted naltrexone releasing during 5 to 6 months
Study NCT00204243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
Study NCT06208930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
Study NCT01007253 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PL nasal spray
Description: 2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
Study NCT01007253 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate (FF)
Description: 2 puffs of FF nasal spray in each nostril once a day for 1 week
Study NCT01007253 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PL eye drops
Description: 1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
Study NCT01007253 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: olopatadine (OLO)
Description: 1 drop of OLO eye drops in each eye once a day for 1 week
Study NCT03473938 — intervention group
Intervention type: DEVICE
Intervention: Spatz3 AIGB
Description: Implantation of Spatz3 AIGB balloon.
Study NCT02012673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic lung volume reduction
Description: Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
Study NCT02551575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of MTX and HCQ
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.
Study NCT02551575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of TCM
Description: Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks.
Study NCT02551575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrative Medicine
Description: Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks.
Study NCT03848078 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. In such ways, microscopic details of lesions and tissues can be visualized. This information can be used to identify a lesion as BCC, and to specify the subtype. Therefore, we assume that the use of the OCT might reduce the number of biopsies and the accompanying morbidity.~The investigator scans 6mm of skin with the OCT (30 seconds) and decides whether the lesion is a BCC or not.
Study NCT01118923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium supplement (magnesium hydroxide/ -oxide)
Description: 3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
Study NCT01118923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo-tablets daily for 12 weeks
Study NCT02299167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dixon's up-and-down method
Description: using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
Study NCT00767871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: 12 week treatment with lexapro
Study NCT04332120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tubal sterilization
Study NCT00081458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injectable subcutaneously daily into thigh or abdomen
Study NCT00081458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d
Description: Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
Study NCT00081458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.1 mg/kg/d
Description: Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
Study NCT03419650 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACTHar
Description: Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
Study NCT04167800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Orthosis, mobilization, strengthening, posture and segmental breathing exercises
Study NCT03927391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: enzalutamide treatment
Study NCT03927391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: enzalutamide treatment
Study NCT03823131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImmunoPulse
Description: Intratumoral
Study NCT03823131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO
Study NCT03823131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03823131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CORVax
Description: Intratumoral
Study NCT03823131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavokinogene telseplasmid
Description: Intratumoral
Study NCT02846402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral HIV Self-Testing
Description: The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
Study NCT03174522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REX-001
Description: REX-001 is administered through an intra-arterial catheter.
Study NCT03174522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered through an intra-arterial catheter.
Study NCT02941003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microscope
Description: Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
Study NCT02941003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunostaining
Description: Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
Study NCT02941003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGS
Description: The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
Study NCT00368550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
Study NCT00368550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14-week treatment period
Study NCT03489564 — intervention group
Intervention type: BEHAVIORAL
Intervention: Active
Description: No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
Study NCT03489564 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sedentary
Description: No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
Study NCT04803500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: single injection of simvastatin gel in the gap around immediately placed implant
Study NCT04803500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
Study NCT00991432 — intervention group
Intervention type: DEVICE
Intervention: INFUSE® Bone Graft
Description: Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
Study NCT00852878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Biofeedback will teach resonant frequency breathing for 6-8 sessions
Study NCT00852878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Protocol
Description: Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
Study NCT03602001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentive eating smartphone application.
Description: A smartphone application that encourages a more attentive eating style.
Study NCT03602001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard dietary advice and text tips.
Description: Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
Study NCT03602001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary advice and text tips.
Description: Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
Study NCT01692756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog or placebo
Study NCT01692756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog then Placebo
Study NCT01692756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog
Study NCT01692756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02292251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Device-assisted therapy
Study NCT02292251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy-based occupational therapy
Study NCT04229901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepaStem
Description: HepaStem will be administered as an intravenous (IV) infusion
Study NCT04229901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an intravenous (IV) infusion
Study NCT01706627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Melatonin
Description: Active Comparator: Drug: Melatonin 10 mg
Study NCT01706627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg Melatonin
Description: Active Comparator: Drug: Melatonin 20 mg
Study NCT01706627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo (identical formulation and delivery, without active ingredient)
Study NCT01257438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluency Plus Endovascular Stent Graft
Description: Treatment of in-stent restenosis
Study NCT01257438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty only
Description: Treatment of in-stent restenosis
Study NCT02456389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-based, escalating levels of monitoring
Description: Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
Study NCT02456389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-based, escalating levels of co-management
Description: Varying use of Hospitalist co-management
Study NCT02456389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative care
Description: Routine postoperative care, as medically indicated
Study NCT03943082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer Educational Materials
Description: Receive FRP brochure
Study NCT03943082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Educational Materials
Description: Receive FRP brochure
Study NCT03943082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Up Care
Description: Receive follow-up phone call
Study NCT03943082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Ancillary studies
Study NCT03943082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study NCT02060162 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: routine standard of care per Ministry of Health protocol including blood draws and examinations.
Study NCT04445649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coma-Recovery-Scale-Revised (CRS-R)
Description: CRS-R assessments (15 minutes) are repeated weekly after study entry
Study NCT00253539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arzoxifene hydrochloride
Description: Given orally
Study NCT00253539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arzoxifene hydrochloride
Description: Given orally
Study NCT00253539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study NCT00253539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02231372 — intervention group
Intervention type: DRUG
Intervention: Berodual® Respimat® solution for inhalation
Study NCT01028521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM3.1-AC100
Description: Solution for sc injection, single ascending doses
Study NCT01028521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for sc injection
Study NCT01874093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Ischemic Stroke System
Description: SPG stimulation and standard of care
Study NCT01874093 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Sham stimulation and standard of care
Study NCT02218489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121
Description: KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study NCT02218489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
Study NCT03781713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KDIGO
Description: Interventions to prevent renal replacement therapy
Study NCT03781713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delta SOFA
Description: interventions to improve SOFA score
Study NCT03781713 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemia
Description: Interventions to prevent new episodes of hypoglycemia in the next 24 hours
Study NCT03781713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug interaction risk D or X
Description: Intervention in the therapeutic plan in order to avoid adverse drug reactions.
Study NCT03781713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial stewardship
Description: Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
Study NCT00002831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
Study NCT00002831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: IV over 4 hours on days -8 and -7.
Study NCT00002831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
Study NCT00002831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given according to clinical grade of GVHD procedures.
Study NCT00002831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
Study NCT00002831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Infusion of stem cells on Day 0.
Study NCT00002831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Stem cell infusion on Day 0.
Study NCT00988663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: patient will receive 5mg daily for 7day then 10 mgm daily
Study NCT00988663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: memantine
Description: patient will receive 5mg daily for 7day then 10 mgm daily
Study NCT00988663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will give placebo that looks like memantine
Study NCT03816072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion
Description: Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.
Study NCT03816072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (\~0.1 Hz).
Study NCT03816072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol
Study NCT03816072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane
Study NCT03331289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
Study NCT03331289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period